德曲妥珠单抗（T-DXd）治疗 HER-2 低表达乳腺癌的研究进展

钊敏 邢

摘要


在 HER-2 阳性乳腺癌中，ERBB2 基因扩增导致 HER-2 过度表达，未接受抗 HER-2 治疗的患者预后较差。德曲妥珠单抗（T-DXd）是一种新型抗体药物偶联物（ADC），其不同于其他 HER-2 靶向药物，能够有效靶向 HER-2 蛋白低表达的肿瘤细胞，并在临床试验中表现出卓越的抗肿瘤活性和耐受性。我们呈现了有关 T-DXd 临床试验的最新研究成果以及其对当前 HER-2 阳性 / 低表达乳腺癌治疗策略的影响。此外，我们还归纳了正在进行的 T-DXd 在 HER-2 低表达乳腺癌患者中的临床试验，并对以往研究中 T-DXd 使用过程中的不良事件进行了总结。总体而言，T-DXd 在治疗 HER-2 阳性、HER-2 低表达晚期乳腺癌方面具备巨大的潜力，并且大多数与 T-DXd 相关的不良事件（AE）属于低级别且可以有效控制。我们期待未来更多关于 T-DXd 的临床试验结果的公布，这些结果有望对当前的治疗标准带来重大影响。

关键词


德曲妥珠单抗；乳腺癌；HER-2 低表达；HER-2 阳性

全文:

PDF

参考


Cortes J, Baselga J, Kellokumpu-Lehtinen P, et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2[J]. JCO. 2005,23(16):3068.

Modi S, Saura C, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer[J]. New England Journal of Medicine, 2020,382(7):610-621.

André F, Park Y H, Kim S B, et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2- positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial[J]. The Lancet, 2023,401(10390):1773-1785.

Cortés J, Kim S B, Chung W P, et al. Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer[J]. New England Journal of Medicine, 2022,386(12):1143-1154.

Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer[J]. N Engl J Med, 2022,387(1):9-20.

Narayan P, Dilawari A, Osgood C, et al. US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer[J]. JCO, 2023,41(11):2108-2116.

Tarantino P, Viale G, Press M F, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer[J]. Annals of Oncology, 2023,34(8):645-659.

Bardia A, Harnden K, Mauro L, et al. Clinical Practices and Institutional Protocols on Prophylaxis, Monitoring, and Management of Selected Adverse Events Associated with Trastuzumab Deruxtecan[J]. Oncologist, 2022,27(8):637-645.




DOI: https://doi.org/10.12346/pmr.v5i3.8511

Refbacks

  • 当前没有refback。